Physician

Andrew Schiff, MD

According to 2025 Medicare claims, Andrew Schiff, MD (NPI: 1801254248) practices critical care (intensivists) in the Camden, NJ market, with the plurality of this provider's patient population coming from Burlington, NJ. This provider's primary affiliated billing organization is VIRTUA MEDICAL GROUP, PA (NPI: 1649226515; TIN: 271348772) and primary practice location at 08053-1855.

Schiff's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 831 traditional Medicare patients, billed 2,131 HCPCS/CPT codes, and received $206,334 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 1,775 prescription claims across 332 beneficiaries totaling $905,006 in drug costs, led by Trelegy Ellipta (Fluticasone/Umeclidin/Vilanter). DME data shows 1,432 claims. Open Payments data shows 78 records totaling $1,315. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $5,079 to $905,006. For DME billing, reported payments moved sharply higher in recent years, from $11,495 to $94,730.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	327	739	$76,933
2020	814	1,997	$199,362
2021	799	2,051	$198,703
2022	899	2,185	$194,985
2023	923	2,256	$202,396
2024	831	2,131	$206,334

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	N/R	N/R	N/R
2016	N/R	20	$5,079
2017	11	46	$8,882
2018	19	37	$17,252
2019	16	62	$40,031
2020	73	242	$66,093
2021	146	681	$173,749
2022	238	1,162	$604,844
2023	254	1,356	$674,801
2024	332	1,775	$905,006

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	24	$10,744
2019	N/R	N/R	N/R
2020	56	336	$24,402
2021	125	612	$17,763
2022	241	873	$47,959
2023	350	1,157	$53,903
2024	477	1,432	$105,855

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	200	204	$149
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	286	467	$109
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	215	349	$105
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	240	410	$67
94729	Test to examine how well the lungs exchange gases	100	103	$50

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	196	9,720	$197,187
Tezspire	Tezepelumab-Ekko	34	1,064	$166,627
Ofev	Nintedanib Esylate	13	390	$158,813
Breo Ellipta	Fluticasone/Vilanterol	122	5,190	$66,184
Eliquis	Apixaban	51	2,790	$52,406

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
E0466	Home ventilator, any type, used with non-invasive interface, (e.g., mask, chest shell)	Y	N/R	37	$37,780
J7677	Revefenacin inhalation solution, fda-approved final product, non-compounded, administered through dme, 1 microgram	N	N/R	20	$16,695
E1390	Oxygen concentrator, single delivery port, capable of delivering 85 percent or greater oxygen concentration at the prescribed flow rate	Y	21	173	$11,162
A7034	Nasal interface (mask or cannula type) used with positive airway pressure device, with or without head strap	N	41	86	$4,206
E0601	Continuous positive airway pressure (cpap) device	Y	27	142	$4,075

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	78	$1,315	GlaxoSmithKline, LLC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Andrew Schiff, MD?

Tedicare shows public-source Medicare data for Andrew Schiff, MD (NPI 1801254248), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Andrew Schiff, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Andrew Schiff, MD?

Andrew Schiff, MD is linked to VIRTUA MEDICAL GROUP, PA (billing NPI 1649226515) in the available physician profile data.

Does Andrew Schiff, MD have Open Payments data?

Andrew Schiff, MD has 78 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.